Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (136)	2/25/1998 8:38:00 AM
From: Jim Roof	Respond to of 4634

BTIM is not in the blood substitute business for the UMPTEENTH TIME! Man there are some thick skulls around here. Somatogen and Biotime's products are completely different, serve totally different purposes and will never compete with each other. While it is true that, if Somatogen gets approval for a true blood substitute, it would act as a volume expander, the price per liter would be astronomically high in comparison to Hextend. This price constraint would never allow for Somatogen to compete for the blood volume expansion market. Besides, I would rather have a royalty deal like Biotime's anyway. Same with Vical and many others. Bill Gates did not sell Microsoft in the early 80's. He opted for a royalty deal with IBM. That seemed to work out OK for him as best as I can tell. Jim